Ferrer Internacional, S.A.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
4
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 10, 2027The maintenance fee for Pharmaceutical topical compositions (US 9,180,200) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Oral formulation for the treatment of cardiovascular diseases (US 10,617,699) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,829,726 | Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,106,202 | Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,022,363 | Pharmaceutical topical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,399,014 | Pharmaceutical topical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,180,200 | Pharmaceutical topical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 10,617,699 | Oral formulation for the treatment of cardiovascular diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 12,533,371 | Multilayer Pharmaceutical or Nutraceutical Solid Dosage Forms Comprising Pyrimidine And/Or Purine Derivatives and B Vitamins, Preparation and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 1 patent in force now held by others · 23 lapsed for an unpaid fee · 28 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
24 no status recorded